• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

VeLVET Trial: Does Laser Therapy Work for Treating Vaginal Atrophy in Menopause?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Genitourinary syndrome of menopause (GSM) includes vaginal moisturizers, lubricants and hormonal therapy
  • Fractionated CO2 laser therapy can lead to tissue remodeling with production of collagen and elastic fibers
  • Paraiso et al. (Menopause, 2020) compared 6-month efficacy and safety for treatment of GSM using fractionated CO2 vaginal laser vs estrogen vaginal cream

METHODS:

  • Multicenter, randomized controlled trial (RCT)
    • Vaginal Laser therapy to Vaginal Estrogen Therapy (VeLVET) trial
  • Participants
    • Menopausal women (no menses for ≥12 months)
    •  Reported significant vaginal dryness (quantified using visual analog scale [VAS] ≥7 cm)
    • Exclusion: Prolapse >stage II | Recent pelvic surgery | Prior mesh surgery | Active genital infection | History of estrogen sensitive malignancy | Autoimmune conditions
  • Interventions
    • Fractionated CO2 laser: 3 intravaginal treatments at least 6 weeks apart
    • Estrogen cream: conjugated estrogen cream 0.5 g intravaginally daily (using applicator or fingertip) for 14 days followed by 0.5 g twice weekly for 24 weeks
  • Primary outcome
    • Visual analog scale vaginal dryness score
  • Secondary outcomes
    • Evaluation of vaginal atrophy | Quality of life symptoms | Assessment of sexual function | Urinary symptoms
  • Statistical analysis
    • Noninferiority study design
    • Predefined noninferiority margin is a difference of 1.0 cm on a 10 cm VAS
    • Primary outcome was presented as the difference in VAS scores between treatments (vaginal estrogen – vaginal laser)

RESULTS:

  • Note: Enrollment closed before the completion of the trial due to FDA requiring Investigational Device Exemption (IDE) for laser therapy | IDE would have required a prolonged cessation of enrollment | Authors chose to complete treatment of enrolled participants and close the study
  • 69 women enrolled | 62 completed the 6-month protocol
    • 30 women were randomized to laser therapy, 32 to estrogen cream
    • Demographics aside from parity (estrogen more parous) did not differ between groups

Primary Outcome

  • Primary outcome: No difference in VAS scores for vaginal dryness
    • No difference between groups (laser -5.48 vs 6.76; P=0.67)
  • No differences found for
    • GSM symptoms (vaginal burning, vaginal itching, and dysuria) | Day-to-Day Impact of Vaginal Aging (DIVA) | Female Sexual Function Index (FSFI) | Urogenital distress inventory (UDI) | Vaginal Health Index (VHI) scores.
  • Vaginal Maturation Index (VMI) was greater in estrogen group (with linear regression adjustment P=0.02) | Data available for 16 patients randomized to laser vs 18 to estrogen
    • Estrogen group 25 +/- 22.6
    • Laser 3.9 +/- 30.6
  • No significant difference found for the following  
    • Improvement between the two groups: Reported as “better or much better”
      • Laser group: 85.8%
      • Estrogen cream group: 70%
    • Satisfaction between the two groups: Reported being either “satisfied or very satisfied”
      • Laser group: 78.5%
      • Estrogen group: 73.3%
  • No serious adverse events were reported

CONCLUSION:

  • Patients treated with CO2 laser reported similar improvement in symptoms similar to that of estrogen cream treatment for genitourinary syndrome of menopause reported improvement in symptoms, sexual, and urinary function, similar to participants receiving estrogen cream therapy
  • 70 to 80% of participants were satisfied with either treatment
  • The authors state

The major limitation of our study was our inability to reach our predetermined statistical power due to early closure of the study because of a request to obtain an IDE to continue. While we cannot state with certainty that CO2 laser treatment is noninferior to vaginal estrogen therapy due to lack of power, we can conclude from our very preliminary results that fractionated CO2 vaginal laser and vaginal estrogen treatment both resulted in improvement in GSM symptoms at 6 months.

Learn More – Primary Sources:

A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Genitourinary Syndrome of Menopause: New Name, Old Problem
More Follow-Up Data from the Estrogen vs Lubricant RCT
Treating Postmenopausal Vaginal Atrophy When Estrogen is Not an Option
Vaginal Moisturizers vs Vaginal Estradiol for Postmenopausal Vulvovaginal Symptoms

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site